About Event
Welcome to the Dry AMD Therapeutics Summit: The Only Industry-Focussed Meeting for The Development of Dry AMD Therapeutics
Built with insights from the leading companies in the dry AMD field, this two-day conference will tackle and explore challenges associated with dry AMD pathophysiology and progression, preclinical models, clinical trial design and novel endpoints, translatable biomarkers and more.
This comprehensive agenda will provide you with a wealth of invaluable insight from top companies such as Apellis, IVERIC, Janssen, Genentech, Novartis with additional academic input from John Hopkins Wilmer Eye Institute, University of Alabama at Birmingham, and University of Rochester.
As the field races towards the first FDA approval, join 100+ of your industry peers and 30+ expert speakers to discuss the future of dry AMD therapeutics and push towards transformative treatments to decrease patient burden and increase treatment benefit.
This scientific program will cover:
Dry AMD Pathophysiology & Progression
With insights from AbbVie, Biojiva and University of Alabama, join the discuss on exploring the role of soft drusen, genetics, oxidative stress, and subretinal drusenoid deposits in dry AMD and GA progression, to inform more effective drug targets which can lead transformative and more effective treatments
Next Generation and Current Utilization of Preclinical Models for dry AMD
With case studies, preclinical data reviews and novel model showcasing, join Oculogenex, Annexon Biosciences and University of Rochester in discussing the novel animal models for gene therapies, light damage animal models for complement inhibition, patient derived iPSCs for better recapitulation of dry AMD’s highly complex mechanisms, increasing the translatability of your drug into the clinic
Novel Structural, Functional Translational Biomarkers for Dry AMD
With lessons from leading companies such as Janssen, Genentech, IVERIC Bio, AbbVie, Novartis and Cognition Therapeutics. These sessions will provide case studies on effective biomarkers with real world data to discuss and review appropriate designation of primary endpoints and utilizing OCT technology to discover novel, structural biomarkers.
Comprehensive Cover of Therapeutic Modalities for Treating Dry AMD
Reviewing preclinical and clinical data from therapeutic modalities including, small molecule, stem cell, gene therapy, compliment inhibition and more, with leading companies such as Apellis, IVERIC, AGTC, Ionis Pharmaceuticals, Endogena Therapeutics, Aviceda Therapeutics, Stealth Biotherapeutics, Cognition Therapeutics and more. These presentations will provide insight into the range of therapeutics approaches such as systemic administration decreasing treatment burden
Four Expert-Led Workshops Covering Patient Retention, Inflammation, Imaging Biomarkers & Development of Preclinical Models
These three-hour, discussive and interactive workshops will be tackling patient retention in elderly patient populations by managing patient expectations and providing appropriate information, the utilization of novel dry AMD imaging biomarkers for better selection of endpoints and trial outcomes, investigate ocular inflammation to help mitigate the discomfort associated with frequent dry AMD therapeutic administration, and discover the development of preclinical models such as the sodium iodate and mast cell degranulation models for dry AMD for better selection of your preclinical model